July 2012 Clinuvel Newsletter
CEO's outlook | Swiss reimbursement underway for SCENESSE® (afamelanotide) | Phase III EPP (US) underway | New video online – Liver transplantation in EPP
Tagged under
Share Price
Buy : 1.9
Sell : 2
First : 1.9
Last : 1.9
High : 1.9
Low : 1.9
ASX: CUV 20 mins delay.
Volume : 640 Trades: 49
Last Traded : 20-May-2013 15:52:51
Investors' Blog Posts
We've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...
Read MoreClinuvel Non-Executive Director Brenda Shanahan has been honoured at The Australian Financial Review and Westpac Group Woman of Influence...
Read More
Since we publicly announced our vitiligo program in 2010, the entire Clinuvel team has aimed to gain a better understand this disease, its...
Read MoreRelated Webcasts
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
